Medical Grade Tranexamic Acid CAS 1197 -18-8 Tranexamic

China Medical Grade Tranexamic Acid CAS 1197-18-8 Tranexamic, Find details about China Tranexamic Acid, Tranexamic from Medical Grade Tranexamic Acid CAS 1197-18-8 Tranexamic

Basic Info.

Model NO.

YT0749

Product Name

Tranexamic Acid

Appearance

White Powder

MOQ

1 Kg

Shelf Life

2 Years

Test Method

HPLC

Sample

Availiable

Packing

Vacuum Packed, Drum

Storage

Cool Dry Place

Molecular Formula

C8h15no2

Molecular Weight

157.21

Einecs

214-818-2

Meiling Point

>300 °c (Lit.)

Boiling Point

281.88°c (Rough Estimate)

Trademark

YTBIO

Specification

99%

Origin

Shaanxi, China

Model NO.

YT0749

Product Name

Tranexamic Acid

Appearance

White Powder

MOQ

1 Kg

Shelf Life

2 Years

Test Method

HPLC

Sample

Availiable

Packing

Vacuum Packed, Drum

Storage

Cool Dry Place

Molecular Formula

C8h15no2

Molecular Weight

157.21

Einecs

214-818-2

Meiling Point

>300 °c (Lit.)

Boiling Point

281.88°c (Rough Estimate)

Trademark

YTBIO

Specification

99%

Origin

Shaanxi, China

Product Desciption

Medical Grade Tranexamic Acid CAS 1197-18-8 Tranexamic

Recently, tranexamic acid has attracted extensive attention because it was added to Yunnan Baiyao
toothpaste.This medicine is a good medicine widely used in clinic. Its important role is to stop bleeding. It is
even considered as a god medicine for stopping bleeding. It is mainly used for stopping bleeding after major
surgery and postpartum. Of course, hemostasis is probably the least reason why many toothpaste additives
hope to have an effect. The discovery of tranexamic acid is legendary. In the 1950s, Japanese pharmacist
Utako Okamoto discovered tranexamic acid, also known as tranexamic acid (a well-known whitening and
freckle removing product in the beauty industry) in the process of looking for hemostatic drugs. Koko Okamoto
was born in 1918 and has been engaged in brain research since 1942. When Japan was defeated in 1945,
there was an extreme lack of research materials. Her original research work was unsustainable and she was
forced to study hemostatic drugs. The reason was that she had blood on her body, and as a woman, she
would bleed every month. It was a good sample for self-study.

Product Name	Tranexamic Acid
CAS NO.	1197-18-8
M.F	C8H15NO2
M.W	157.21
EINECS	214-818-2
Assay(HPLC)	99.0%
Appearance	White Powder
Grade	Cosmetic grade,Pharmaceutical grade
Package	25kgs/Drum

Clinically, it is mainly used for all kinds of bleeding caused by hyperfibrinolysis.

Tranexamic acid is a synthetic lysine analogue, which can competitively bind to the lysine binding site on
plasminogen and plasmin, so as to competitively inhibit the degradation of fibrin, reduce fibrinolytic activity
and play a role in promoting coagulation. Theoretically, the use of tranexamic acid can lead to insufficient
fibrinolytic activity, so it may increase the risk of postoperative thrombotic events.
Medical Grade Tranexamic Acid CAS 1197-18-8 Tranexamic

Main clinical application:

1. Trauma
Studies have shown that tranexamic acid can safely and reliably reduce the mortality of patients with traumatic
bleeding. In view of this, tranexamic acid, a cheap and non patented drug, has been included in the who list
of essential drugs and will be widely used in high, medium and low-income countries in the world.
2. Craniocerebral trauma
Studies have shown that patients receiving tranexamic acid are less likely to have progressive bleeding and
have a decreasing trend in mortality.
Although neither of these two studies has reached a very clear conclusion, it still suggests that tranexamic
acid may improve the prognosis of traumatic brain injury, which will lay a foundation for follow-up studies.
For example, the crash-3 study, which will soon be implemented and recruit up to 10000 patients with
craniocerebral injury, will provide reliable evidence for the efficacy of tranexamic acid in improving mortality
and disability.
3. Excessive menstrual blood
Tranexamic acid can significantly reduce the blood loss of women with menorrhagia. A Cochrane systematic
review of antifibrinolytic agents (mainly tranexamic acid) in the treatment of menorrhagia pointed out that
antifibrinolytic agents can reduce blood loss in women with menorrhagia more than placebo or other treatments
without increasing the incidence of side effects. The US Food and Drug Administration approved tranexamic
acid oral tablets as a treatment for women with severe menorrhea on November 13, 2009.
4. Postpartum hemorrhage
Studies have shown that tranexamic acid significantly reduces the amount of postpartum hemorrhage.
However, due to the low methodological quality of the three randomized trials, there is no evidence from
high-quality studies to support the application of antifibrinolytic drugs in postpartum hemorrhage. At present,
a randomized double-blind placebo-controlled trial called Woman (the world material antifibrinolytic trial) is
being carried out. It will recruit 15000 patients worldwide to provide reliable evidence for the improvement
of mortality and hysterectomy rate of patients with postpartum hemorrhage by early application of tranexamic
acid.
Medical Grade Tranexamic Acid CAS 1197-18-8 Tranexamic